Codiak Biosciences Inc Quick Ratio (CDAK) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Codiak Biosciences Inc   (NASDAQ: CDAK)

Codiak Biosciences Inc 's Quick Ratio

CDAK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 4.52 below Codiak Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 113 other companies have achieved higher Quick Ratio than Codiak Biosciences Inc in third quarter 2022. While Quick Ratio total ranking has improved so far during the Q3 2022 to 1320, from total ranking in the second quarter 2022 at 1406.

Explain Quick Ratio?
How much Cash & cash equivalents CDAK´s has?
What are CDAK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CDAK Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change -44.62 % -50.93 % -34.15 % 51.55 % -36.64 %
Y / Y Cash & cash equivalent Change -47.49 % -63.24 % -56.63 % -13.47 % 103.94 %
Quick Ratio MRQ 4.52 4.58 6.44 3.14 4.77
CDAK's Total Ranking # 1320 # 1406 # 1195 # 2120 # 1610
Seq. Current Liabilities Change 25.47 % 4.06 % -64.23 % 18.58 % 11.17 %
Seq. Cash & cash equivalent Change 23.88 % -26.04 % -26.57 % -21.96 % -13.28 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 114
Healthcare Sector # 532
Overall Market # 1279


Quick Ratio Statistics
High Average Low
9.79 5.06 1.48
(Mar 31 2021)   (Sep 30 2020)




Financial Statements
Codiak Biosciences Inc 's Current Liabilities $ 11 Millions Visit CDAK's Balance sheet
Codiak Biosciences Inc 's Cash & cash equivalent $ 52 Millions Visit CDAK's Balance sheet
Source of CDAK's Sales Visit CDAK's Sales by Geography


Cumulative Codiak Biosciences Inc 's Quick Ratio

CDAK's Quick Ratio for the trailling 12 Months

CDAK Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth -21.67 % -21.85 % -11.4 % 12.45 % 31.25 %
Y / Y Cash & cash equivalent TTM Growth -47.39 % -28.18 % -1.48 % 90.12 % 227.55 %
Quick Ratio TTM 4.22 4.34 4.77 5.44 6.28
Total Ranking TTM # 4344 # 4337 # 4250 # 4211 # 4215
Seq. Current Liabilities TTM Growth -14.62 % -13.05 % -5.9 % 12.13 % -14.81 %
Seq. Cash & cash equivalent TTM Growth -17.1 % -20.8 % -17.59 % -2.78 % 13.18 %

Quick ratio ranking by company, industry and sector >> Back to CDAK Financial Strength Comparisons >> Go to Compare CDAK Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CDAK's Current Liabilities to $11.44 millions, cumulative Quick Ratio to 4.22 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 190 other companies have achieved higher Quick Ratio than Codiak Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 4337 to 4344.

Explain Quick Ratio?
How much Cash & cash equivalents CDAK´s has?
What are CDAK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 191
Healthcare Sector # 1149
Within the Market # 4344


trailing twelve months Quick Ratio Statistics
High Average Low
5.59 4.18 3.14
(Sep 30 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Rubius Therapeutics Inc   11.92 $ 103.884  Millions$ 8.717  Millions
Allogene Therapeutics Inc   11.30 $ 552.229  Millions$ 48.872  Millions
Aura Biosciences Inc   11.21 $ 111.701  Millions$ 9.964  Millions
Ginkgo Bioworks Holdings Inc   10.44 $ 1,302.603  Millions$ 124.818  Millions
Scholar Rock Holding Corp  10.19 $ 343.655  Millions$ 33.736  Millions
Caribou Biosciences Inc   10.18 $ 293.369  Millions$ 28.814  Millions
Omega Therapeutics Inc   10.09 $ 148.346  Millions$ 14.698  Millions
Editas Medicine Inc   9.92 $ 419.617  Millions$ 42.289  Millions
Passage Bio Inc   9.89 $ 213.758  Millions$ 21.619  Millions
Humacyte Inc   9.59 $ 171.731  Millions$ 17.906  Millions
Tscan Therapeutics Inc   9.28 $ 137.306  Millions$ 14.799  Millions
Solid Biosciences Inc   9.17 $ 142.157  Millions$ 15.510  Millions
Invivyd Inc   9.08 $ 418.669  Millions$ 46.126  Millions
Surrozen Inc   9.06 $ 78.395  Millions$ 8.654  Millions
Vectivbio Holding Ag  8.95 $ 221.416  Millions$ 24.741  Millions
Revolution Medicines Inc   8.94 $ 655.013  Millions$ 73.271  Millions
Tenaya Therapeutics Inc   8.44 $ 149.450  Millions$ 17.716  Millions
Inmune Bio Inc   8.33 $ 57.405  Millions$ 6.895  Millions
Inhibikase Therapeutics Inc   8.26 $ 26.534  Millions$ 3.213  Millions
Kodiak Sciences Inc   8.19 $ 537.395  Millions$ 65.600  Millions
Surface Oncology Inc   8.13 $ 146.350  Millions$ 17.992  Millions
Bioatla Inc   7.98 $ 178.120  Millions$ 22.327  Millions
Voyager Therapeutics Inc   7.92 $ 131.638  Millions$ 16.612  Millions
Curis Inc   7.81 $ 98.689  Millions$ 12.639  Millions
Miromatrix Medical inc   7.77 $ 31.541  Millions$ 4.058  Millions
Engene Therapeutics Inc   7.61 $ 20.434  Millions$ 2.686  Millions
Vir Biotechnology Inc   7.58 $ 2,336.635  Millions$ 308.203  Millions
Exscientia Plc  7.40 $ 648.982  Millions$ 87.745  Millions
Senti Biosciences Holdings Inc   7.26 $ 114.940  Millions$ 15.837  Millions
Tectonic Therapeutic Inc   7.16 $ 115.968  Millions$ 16.192  Millions

Date modified: 2026-09-26T07:39:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.